Traci McDonald
Family · Elk Point, SDNPI 1588044846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,261, 6.5 times the $194 reported in 2021. Among family clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$765
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$464
- Otsuka America Pharmaceutical, Inc.$449
- Johnson & Johnson$256
- Alkermes, Inc.$208
- Neurocrine Biosciences, Inc.$196
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $765 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $464 |
| Otsuka America Pharmaceutical, Inc. | 29 | $449 |
| Johnson & Johnson | 8 | $256 |
| Alkermes, Inc. | 9 | $208 |
| Neurocrine Biosciences, Inc. | 3 | $196 |
| Vanda Pharmaceuticals Inc. | 10 | $190 |
| Pfizer | 10 | $170 |
| Lilly USA, LLC | 11 | $151 |
| Corium, LLC | 13 | $131 |
| Supernus Pharmaceuticals, Inc. | 3 | $117 |
| Boehringer Ingelheim | 6 | $106 |
| Exact Sciences | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Novo Nordisk | 3 | $44 |
| Astellas Pharma US Inc | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Amgen | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Mylan Specialty L.p. | 1 | $24 |
| Abbott | 1 | $18 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Novartis | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$125
- INVEGA TRINZA$118
How this compares
$3,698 in reported general payments places this provider in the 95th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $59,463 |
| OzempicSemaglutide | 37 | $47,978 |
| Invega SustennaPaliperidone Palmitate | 13 | $43,054 |
| VraylarCariprazine Hcl | 34 | $29,095 |
| RexultiBrexpiprazole | 25 | $24,676 |
| EliquisApixaban | 35 | $20,135 |
| TrulicityDulaglutide | 16 | $14,372 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $11,692 |
| JardianceEmpagliflozin | 15 | $9,955 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 15 | $3,179 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,047 |
| Potassium Chloride | 36 | $2,864 |
| Aripiprazole | 88 | $2,701 |
| Bupropion XlBupropion Hcl | 118 | $1,823 |
| Buspirone Hcl | 51 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $151 | $74,389107 claims |
| Novo NordiskOzempic | $44 | $47,97837 claims |
| Johnson & JohnsonInvega Sustenna | $256 | $43,05413 claims |
| AbbVieVraylar | $765 | $29,09534 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $449 | $24,67625 claims |
| PfizerEliquis | $170 | $20,13535 claims |
| Boehringer IngelheimJardiance | $106 | $9,95515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family providers in South Dakota.
Other family in Elk Point
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Claudia HouglandRapid City$9K
- Maria AzpeitiaDakota Dunes$8K
- Michelle VanhoveSioux Falls$7K
- Sandra EricksonHerreid$7K
- Melissa OwensRapid City$6K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Michelle BrandenburgHuron$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.